AppYea, Inc. (APYP) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
APYP, 0.02$ (piyasa değeri 13M) fiyatla Technology işi olan AppYea, Inc.'i temsil ediyor. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 50/100 puan alıyor.
Son analiz: 15 Mar 2026AppYea, Inc. (APYP) Teknoloji Profili ve Rekabetçi Konumu
AppYea, Inc. develops and patents digital health solutions for sleep apnea and snoring, focusing on sensor-based monitoring and real-time detection. Their SleepX app and DreamIT wristband aim to provide accessible and convenient sleep disorder management, positioning them in the growing market for digital health technologies.
Yatırım Tezi
AppYea, Inc. presents a focused investment opportunity within the digital health sector, specifically targeting the sleep apnea and snoring market. With a market capitalization of $0.01 billion and a gross margin of 15.8%, the company is positioned to capitalize on the increasing demand for accessible and convenient sleep monitoring and treatment solutions. Key value drivers include the continued development and refinement of their SleepX and DreamIT product lines, expansion into new markets, and potential partnerships with healthcare providers. The company's low beta of 0.11 suggests relatively low volatility compared to the broader market. However, investors should be aware of the risks associated with investing in OTC-listed companies and the competitive landscape of the digital health market.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.01 billion, reflecting its current valuation in the OTC market.
- Gross margin of 15.8%, indicating the profitability of its products before operating expenses.
- Free cash flow of $-0.00B, highlighting the need for careful cash management and potential future financing.
- Beta of 0.11, suggesting lower volatility compared to the overall market.
- Focus on the digital health market for sleep apnea and snoring, addressing a significant and growing health concern.
Güçlü Yönler
- Proprietary technology for sleep monitoring and treatment.
- Integrated solution combining app and wearable device.
- Focus on the growing market for digital health solutions.
- Low beta indicating lower volatility.
Zayıflıklar
- Limited financial resources.
- Small number of employees.
- Dependence on single product line.
- OTC listing presents liquidity and regulatory challenges.
Katalizörler
- Upcoming: Potential partnerships with healthcare providers and sleep clinics.
- Ongoing: Continued development and refinement of SleepX and DreamIT product lines.
- Ongoing: Expansion into new geographic markets.
- Ongoing: Increased adoption of telehealth and remote patient monitoring.
Riskler
- Potential: Competition from established medical device companies.
- Potential: Technological obsolescence.
- Ongoing: Limited financial resources.
- Ongoing: OTC listing presents liquidity and regulatory challenges.
- Potential: Regulatory changes in the healthcare industry.
Büyüme Fırsatları
- Expansion into New Markets: AppYea can expand its market reach beyond its current base by targeting new geographic regions and demographic segments. The global market for sleep apnea devices is projected to reach billions of dollars, offering significant growth potential for AppYea's SleepX and DreamIT products. Timeline: Ongoing.
- Strategic Partnerships: Collaborating with healthcare providers, sleep clinics, and insurance companies can accelerate adoption of AppYea's solutions and increase market penetration. Partnerships can provide access to established distribution channels and patient networks. Timeline: Ongoing.
- Product Innovation: Continuous innovation and development of new features for the SleepX and DreamIT product lines can enhance their value proposition and attract new customers. This includes incorporating advanced sensor technologies, AI-powered analytics, and personalized treatment plans. Timeline: Ongoing.
- Direct-to-Consumer Marketing: Implementing targeted marketing campaigns to reach consumers directly through online channels, social media, and digital advertising can increase brand awareness and drive sales. This approach allows AppYea to bypass traditional healthcare channels and reach a wider audience. Timeline: Ongoing.
- Integration with Telehealth Platforms: Integrating AppYea's solutions with telehealth platforms can provide remote monitoring and treatment options for patients with sleep apnea and snoring. This integration can enhance patient engagement and improve treatment outcomes. Timeline: Ongoing.
Fırsatlar
- Expansion into new geographic markets.
- Strategic partnerships with healthcare providers.
- Development of new features and products.
- Increased adoption of telehealth and remote patient monitoring.
Tehditler
- Competition from established medical device companies.
- Technological obsolescence.
- Regulatory changes in the healthcare industry.
- Economic downturn affecting consumer spending.
Rekabet Avantajları
- Proprietary Algorithms: Unique algorithms for monitoring breathing and detecting snoring/sleep apnea events.
- Patented Technology: Designs and patents for sensor monitoring and software solutions.
- Integrated Solution: Combination of smartphone application and wearable device for comprehensive sleep monitoring and treatment.
APYP Hakkında
Founded in 2012 and based in Rehovot, Israel, AppYea, Inc. operates as a digital health company focused on designing, patenting, and producing sensor monitoring and software solutions for snoring and sleep apnea. The company's core product offerings include the SleepX App and DreamIT wristband. The SleepX App is a smartphone application that employs unique algorithms to monitor breathing and detect snoring events in real time. Complementing the app, the DreamIT wristband features various sensors and interfaces with the SleepX App to provide treatment for snoring. AppYea also offers SleepX PRO, an application designed to monitor breathing and detect sleep apnea incidents, and DreamIT PRO, a wristband that interfaces with the SleepX PRO app for sleep apnea treatment. AppYea aims to provide accessible and convenient solutions for individuals suffering from sleep-related breathing disorders, leveraging technology to improve sleep quality and overall health.
Ne Yaparlar
- Designs and patents sensor monitoring solutions.
- Develops software for snoring and sleep apnea detection.
- Produces the SleepX App for real-time snoring monitoring.
- Manufactures the DreamIT wristband for snoring treatment.
- Offers SleepX PRO for sleep apnea detection.
- Provides DreamIT PRO for sleep apnea treatment.
İş Modeli
- Develops and sells sensor-based monitoring devices (DreamIT wristband).
- Offers smartphone applications (SleepX App, SleepX PRO) for sleep monitoring and treatment.
- Generates revenue through direct sales to consumers.
- Potential for future revenue through partnerships with healthcare providers and insurance companies.
Sektör Bağlamı
AppYea, Inc. operates within the rapidly expanding digital health market, specifically targeting sleep apnea and snoring solutions. The industry is characterized by increasing adoption of telehealth and remote patient monitoring technologies. The competitive landscape includes established medical device companies, as well as emerging digital health startups. AppYea's focus on sensor-based monitoring and smartphone integration positions it to capitalize on the growing demand for accessible and convenient sleep disorder management.
Kilit Müşteriler
- Individuals suffering from snoring.
- Individuals suffering from sleep apnea.
- Healthcare providers seeking remote patient monitoring solutions.
- Sleep clinics and sleep disorder centers.
Finansallar
Grafik & Bilgi
AppYea, Inc. (APYP) hisse senedi fiyatı: $0.02 (+0.00, +20.67%)
Son Haberler
-
Stocks That Hit 52-Week Lows On Monday
· 10 Şub 2020
-
Stocks That Hit 52-Week Lows On Tuesday
· 3 Ara 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· 9 Eki 2019
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
APYP için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
APYP için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, APYP'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Yakir Abady
CEO
Yakir Abady serves as the CEO of AppYea, Inc. His background includes experience in managing and leading technology-driven companies. He is responsible for overseeing the company's strategic direction, product development, and overall operations. His leadership is focused on driving innovation and growth in the digital health market, particularly in the area of sleep apnea and snoring solutions.
Sicil: Under Yakir Abady's leadership, AppYea, Inc. has focused on developing and commercializing its SleepX and DreamIT product lines. Key milestones include securing patents for its sensor monitoring technology and expanding its market reach through online channels. He is currently focused on securing partnerships to expand market reach.
APYP OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that AppYea, Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited Liquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of Transparency: Limited financial reporting and regulatory oversight increase the risk of fraud and manipulation.
- Financial Instability: Companies in the OTC Other tier may be financially distressed or have limited operating history.
- Dilution Risk: Frequent stock dilutions can significantly reduce the value of existing shares.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory scrutiny than exchange-listed companies.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and potential for dilution.
- Review the company's legal and regulatory compliance.
- Check for any red flags or warning signs in the company's history.
- Understand the risks associated with investing in OTC-listed companies.
- Patents for sensor monitoring technology.
- Development of SleepX and DreamIT product lines.
- Focus on the growing market for digital health solutions.
APYP Technology Hisse Senedi SSS
APYP için değerlendirilmesi gereken temel faktörler nelerdir?
AppYea, Inc. (APYP) şu anda yapay zeka skoru 50/100, orta puanı gösteriyor. Temel güçlü yan: Proprietary technology for sleep monitoring and treatment.. İzlenmesi gereken birincil risk: Potential: Competition from established medical device companies.. Bu bir finansal tavsiye değildir.
APYP MoonshotScore'u nedir?
APYP şu anda MoonshotScore'da 50/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
APYP verileri ne sıklıkla güncellenir?
APYP fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler APYP hakkında ne diyor?
APYP için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
APYP'a yatırım yapmanın riskleri nelerdir?
APYP için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from established medical device companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
APYP'ın P/E oranı nedir?
APYP için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için APYP'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
APYP aşırı değerli mi, yoksa düşük değerli mi?
AppYea, Inc. (APYP)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
APYP'ın temettü verimi nedir?
AppYea, Inc. (APYP) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Information is based on available data as of 2026-03-15.
- OTC market data may be limited or unreliable.
- Analyst coverage may be limited due to the company's size and OTC listing.